MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte total assets

Total assets on the balance sheet at the end of each period.

MaxCyte's total assets was $182.48M at Sep 30, 2026. For fiscal 2025 it was $202.51M, down 15.4% from the year before. The highest annual figure on record is $286.65M in fiscal 2022.

Annual total assets

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$202.51M	-15.4%
FY2024	Dec 31, 2024	$239.47M	-10.7%
FY2023	Dec 31, 2023	$268.27M	-6.4%
FY2022	Dec 31, 2022	$286.65M	+0.9%
FY2021	Dec 31, 2021	$284.12M	+448.7%
FY2020	Dec 31, 2020	$51.78M	–

Quarterly total assets

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$182.48M	-14.5%
Q2 FY2026	Jun 30, 2026	$184.67M	-16.0%
Q1 FY2026	Mar 31, 2026	$194.47M	-15.4%
Q4 FY2025	Dec 31, 2025	$202.51M	-15.4%
Q3 FY2025	Sep 30, 2025	$213.48M	-14.1%
Q2 FY2025	Jun 30, 2025	$219.75M	-12.6%
Q1 FY2025	Mar 31, 2025	$229.96M	-10.8%
Q4 FY2024	Dec 31, 2024	$239.47M	-10.7%
Q3 FY2024	Sep 30, 2024	$248.61M	-6.8%
Q2 FY2024	Jun 30, 2024	$251.50M	-7.3%
Q1 FY2024	Mar 31, 2024	$257.93M	-8.4%
Q4 FY2023	Dec 31, 2023	$268.27M	-6.4%
Q3 FY2023	Sep 30, 2023	$266.73M	-6.9%
Q2 FY2023	Jun 30, 2023	$271.20M	-6.4%
Q1 FY2023	Mar 31, 2023	$281.54M	-3.2%
Q4 FY2022	Dec 31, 2022	$286.65M	+0.9%
Q3 FY2022	Sep 30, 2022	$286.41M	+3.1%
Q2 FY2022	Jun 30, 2022	$289.78M	+211.1%
Q1 FY2022	Mar 31, 2022	$290.96M	+461.9%
Q4 FY2021	Dec 31, 2021	$284.12M	–
Q3 FY2021	Sep 30, 2021	$277.69M	–
Q2 FY2021	Jun 30, 2021	$93.15M	–
Q4 FY2020	Dec 31, 2020	$51.78M	–